Mineralys Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Mineralys Therapeutics, Inc. Common Stock (MLYS) has an Asset Resilience Ratio of 62.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Mineralys Therapeutics, Inc. Common Stoc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Mineralys Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See MLYS book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Mineralys Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MLYS stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $376.03 Million | 62.68% |
| Total Liquid Assets | $376.03 Million | 62.68% |
Asset Resilience Insights
- Very High Liquidity: Mineralys Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 62.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Mineralys Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Mineralys Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Mineralys Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Mineralys Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 40.84% | $84.10 Million | $205.90 Million | -33.58pp |
| 2023-12-31 | 74.42% | $187.26 Million | $251.64 Million | +54.84pp |
| 2022-12-31 | 19.58% | $22.41 Million | $114.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $11.12 Million | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, … Read more